ABSTRACT
Objectives The Milan metropolitan area in Northern Italy was among the most severely hit by the SARS-CoV-2 outbreak. The epidemiological trends of mild COVID-19 are however still unknown. The aim of this study was to examine the seroprevalence of SARS-CoV-2 infection in healthy asymptomatic adults, the risk factors, and laboratory correlates.
Design We conducted a cross-sectional study during the outbreak. Presence of anti-SARS-CoV-2 IgM/IgG antibodies against the Nucleocapsid protein was assessed by a lateral flow immunoassay.
Setting Blood center at a leading academic hospital serving as COVID-19 referral center.
Participants We considered a random sample of blood donors since the start of the outbreak (February 24th to April 8th 2020, n=789).
Main outcome measures The main outcome was the prevalence of IgG/IgM anti-SARS-CoV-2 antibodies.
Results The test had a 98.3% specificity and 100% sensitivity, and for IgG+ was validated in a subset by an independent ELISA against the Spike protein (N=34, P<0.001). At the start of the outbreak, the overall seroprevalence of SARS-CoV-2 was 4.6% (2.3 to 7.9; P<0.0001 vs. 120 historical controls). During the study period characterized by a gradual implementation of social distancing measures, there was a progressive increase in seroprevalence to 7.1% (4.4 to 10.8), due to a rise in IgG+ to 5% (2.8 to 8.2; P=0.004 for trend, adjusted weekly increase 2.7±1.3%), but not of IgM+ (P=NS). At multivariate logistic regression analysis, seroconversion to IgG+ was more frequent in younger (P=0.043), while recent infections (IgM+) in older individuals (P=0.002). IgM+ was independently associated with higher triglycerides, eosinophils, and lymphocytes (P<0.05).
Conclusions SARS-CoV-2 infection was already circulating in Milan at the outbreak start. Social distancing may have been more effective in younger individuals, and by the end of April 4.4-10.8% of healthy adults had evidence of seroconversion. Asymptomatic infection may affect lipid profile and blood count.
What is already know on this topic
SARS-CoV-2 causes COVID-19, associated with a high mortality rate, but may be asymptomatic in a still undefined fraction of individuals.
COVID-19 is associated with altered hematological, inflammatory and biochemical parameters, but the laboratory correlates of non-severe infection are unknown.
A severe COVID-19 outbreak severely hit Milan at the end of February 2020, but the number of infected individuals and risk factors remain unclear.
What this study adds
SARS-CoV-2 was already circulating in Milan at the COVID-19 outbreak start on February 2020, with only 1 in 20 infected individuals being symptomatic and diagnosed.
Social distancing may have been more effective in reducing new infections in younger individuals, and by the end of April 4.4-10.8% of healthy asymptomatic adults had evidence of seroconversion.
Asymptomatic infection may affect lipid profile and be associated with higher circulating lymphocytes and eosinophils.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NA
Funding Statement
The study was funded by Ricerca Corrente Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Institutional funding to DP); COVID-19 Network Registry Biobanking, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (LV); Ricerca Finalizzata Ministero della Salute (Italian Ministry of Health) RF-2016-02364358 (LV), Fondazione Sviluppo Ca’ Granda for the project Liver-Bible - PR-0361 (LV); the EU Programme Horizon 2020 (under grant agreement No. 777377) for the project LITMUS (LV).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The study database is available upon request for collaborative studies.
